other material
confidence high
sentiment neutral
materiality 0.50
GT Biopharma issues pre-funded warrant to Cytovance for 326,251 shares as service consideration
GT Biopharma, Inc.
- Issued pre-funded warrant to purchase up to 326,251 shares of common stock at $0.0001 per share.
- Aggregate exercise price of $846,562.50 was pre-funded via services rendered by Cytovance Biologics.
- Warrant is immediately exercisable with a beneficial ownership limitation; no cash received.
- Issued without registration under Section 4(a)(2) of Securities Act as a private transaction.